USD 339.23
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.24 Billion EUR | 2.53% |
2022 | 1.21 Billion EUR | 14.31% |
2021 | 1.06 Billion EUR | 13.89% |
2020 | 934.19 Million EUR | -0.44% |
2019 | 938.34 Million EUR | 7.99% |
2018 | 868.93 Million EUR | 0.82% |
2017 | 861.88 Million EUR | -1.14% |
2016 | 871.82 Million EUR | 2.25% |
2015 | 852.62 Million EUR | 10.28% |
2014 | 773.11 Million EUR | 5.03% |
2013 | 736.07 Million EUR | 5.89% |
2012 | 695.15 Million EUR | 11.57% |
2011 | 623.05 Million EUR | 8.77% |
2010 | 572.83 Million EUR | 22.55% |
2009 | 467.41 Million EUR | 5.43% |
2008 | 443.35 Million EUR | 1.1% |
2007 | 438.54 Million EUR | 9.19% |
2006 | 401.63 Million EUR | 7.85% |
2005 | 372.4 Million EUR | 5.98% |
2004 | 351.4 Million EUR | -0.95% |
2003 | 354.75 Million EUR | -3.58% |
2002 | 367.93 Million EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 351.46 Million EUR | 10.45% |
2024 Q2 | 351.46 Million EUR | 0.0% |
2023 FY | 1.24 Billion EUR | 2.53% |
2023 Q2 | 610.46 Million EUR | 100.0% |
2023 Q3 | 318.21 Million EUR | -47.87% |
2023 Q4 | 318.21 Million EUR | 0.0% |
2023 Q1 | 305.23 Million EUR | -49.11% |
2022 Q1 | 308.18 Million EUR | -42.35% |
2022 Q2 | 616.36 Million EUR | 100.0% |
2022 Q3 | 299.91 Million EUR | -51.34% |
2022 Q4 | 599.82 Million EUR | 100.0% |
2022 FY | 1.21 Billion EUR | 14.31% |
2021 Q4 | 534.55 Million EUR | 100.0% |
2021 FY | 1.06 Billion EUR | 13.89% |
2021 Q2 | 529.41 Million EUR | 100.0% |
2021 Q1 | 264.7 Million EUR | -41.94% |
2021 Q3 | 267.27 Million EUR | -49.51% |
2020 FY | 934.19 Million EUR | -0.44% |
2020 Q2 | 478.3 Million EUR | 100.0% |
2020 Q1 | 239.15 Million EUR | -49.61% |
2020 Q4 | 455.89 Million EUR | 100.0% |
2020 Q3 | 227.94 Million EUR | -52.34% |
2019 Q2 | 231.86 Million EUR | 0.0% |
2019 Q4 | 474.6 Million EUR | 100.0% |
2019 FY | 938.34 Million EUR | 7.99% |
2019 Q3 | 237.3 Million EUR | 2.35% |
2019 Q1 | 231.86 Million EUR | 5.64% |
2018 Q3 | 219.48 Million EUR | 2.1% |
2018 FY | 868.93 Million EUR | 0.82% |
2018 Q2 | 214.98 Million EUR | 0.0% |
2018 Q1 | 214.98 Million EUR | 1.32% |
2018 Q4 | 219.48 Million EUR | 0.0% |
2017 Q3 | 212.17 Million EUR | -3.01% |
2017 Q2 | 218.76 Million EUR | 0.0% |
2017 Q4 | 212.17 Million EUR | 0.0% |
2017 FY | 861.88 Million EUR | -1.14% |
2017 Q1 | 218.76 Million EUR | -0.98% |
2016 Q4 | 220.93 Million EUR | 0.0% |
2016 Q1 | 214.98 Million EUR | 2.29% |
2016 FY | 871.82 Million EUR | 2.25% |
2016 Q3 | 220.93 Million EUR | 2.77% |
2016 Q2 | 214.98 Million EUR | 0.0% |
2015 Q2 | 216.14 Million EUR | 0.0% |
2015 FY | 852.62 Million EUR | 10.28% |
2015 Q4 | 210.17 Million EUR | 0.0% |
2015 Q3 | 210.17 Million EUR | -2.76% |
2015 Q1 | 216.14 Million EUR | 6.27% |
2014 Q1 | 183.16 Million EUR | 0.61% |
2014 FY | 773.11 Million EUR | 5.03% |
2014 Q3 | 203.39 Million EUR | 11.04% |
2014 Q4 | 203.39 Million EUR | 0.0% |
2014 Q2 | 183.16 Million EUR | 0.0% |
2013 Q1 | 185.98 Million EUR | 0.0% |
2013 FY | 736.07 Million EUR | 5.89% |
2013 Q3 | 182.05 Million EUR | -2.11% |
2013 Q2 | 185.98 Million EUR | 0.0% |
2013 Q4 | 182.05 Million EUR | 0.0% |
2012 FY | 695.15 Million EUR | 11.57% |
2011 FY | 623.05 Million EUR | 8.77% |
2010 FY | 572.83 Million EUR | 22.55% |
2009 FY | 467.41 Million EUR | 5.43% |
2008 FY | 443.35 Million EUR | 1.1% |
2007 FY | 438.54 Million EUR | 9.19% |
2006 FY | 401.63 Million EUR | 7.85% |
2005 FY | 372.4 Million EUR | 5.98% |
2004 FY | 351.4 Million EUR | -0.95% |
2003 FY | 354.75 Million EUR | -3.58% |
2002 FY | 367.93 Million EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AstraZeneca PLC | 46.91 Billion USD | 97.342% |
Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 97.229% |
CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 96.035% |
Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -8833.875% |
Novartis AG | 46.66 Billion USD | 97.328% |
PT Kalbe Farma Tbk. | 1.97 Billion USD | 37.0% |